Anticancer agent 50

Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma[1].

Research Areas >> Cancer

Signaling Pathways >> Apoptosis >> MDM-2/p53

Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein

Anticancer agent 50 (compound 6) (0-100 µM) shows cytotoxic effects with IC50s of 0.67, 0.90 µM for sensitive parental (PAR) and resistant (MDR) mouse T-lymphoma cells, respectively[1]. Anticancer agent 50 (0-100 µM) shows antiproliferative effects with IC50s of 3.84, 1.34 µM for sensitive parental (PAR) and resistant (MDR) mouse T-lymphoma cells, respectively[1]. Anticancer agent 50 (0.1, 0.5, 2 µM; 24 h) inhibits cell cycle progression through the reduction of the expression of cyclin D1 and inhibits cell proliferation by inducing p53 expression[1]. Anticancer agent 50 (0.1, 0.5, 2, 10 µM; 72 h) inhibits cell growth by 12% in SH-SY5Y cells[1]. RT-PCR[1] Cell Line: JURKAT cells Concentration: 0.1, 0.5, 2 µM Incubation Time: 24 h Result: Significantly reduced cyclin D1 expression and increased the level of p53.

[1]. Ali W, et al. Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma. Eur J Med Chem. 2020 Aug 15;200:112435.